Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.45 Billion KRW | -18.2% |
| 2022 | 5.44 Billion KRW | -33.21% |
| 2021 | 8.14 Billion KRW | -27.0% |
| 2020 | 11.16 Billion KRW | -39.39% |
| 2019 | 18.41 Billion KRW | -7.48% |
| 2018 | 19.9 Billion KRW | -21.94% |
| 2017 | 25.5 Billion KRW | -7.27% |
| 2016 | 27.5 Billion KRW | 450.0% |
| 2015 | 5 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.05 Billion KRW | 0.0% |
| 2024 Q2 | - KRW | 0.0% |
| 2023 Q1 | 5.09 Billion KRW | -6.48% |
| 2023 FY | 4.45 Billion KRW | -18.2% |
| 2023 Q4 | 4.45 Billion KRW | -5.11% |
| 2023 Q3 | 4.69 Billion KRW | -8.53% |
| 2023 Q2 | 5.12 Billion KRW | 0.76% |
| 2022 FY | 5.44 Billion KRW | -33.21% |
| 2022 Q2 | 5.86 Billion KRW | -6.03% |
| 2022 Q1 | 6.23 Billion KRW | -23.46% |
| 2022 Q4 | 5.44 Billion KRW | -10.72% |
| 2022 Q3 | 6.09 Billion KRW | 4.01% |
| 2021 FY | 8.14 Billion KRW | -27.0% |
| 2021 Q2 | 7.75 Billion KRW | -19.12% |
| 2021 Q1 | 9.58 Billion KRW | -14.11% |
| 2021 Q3 | 5.99 Billion KRW | -22.69% |
| 2021 Q4 | 8.14 Billion KRW | 35.92% |
| 2020 FY | 11.16 Billion KRW | -39.39% |
| 2020 Q1 | 16.54 Billion KRW | -10.17% |
| 2020 Q4 | 11.16 Billion KRW | -14.18% |
| 2020 Q3 | 13 Billion KRW | -12.47% |
| 2020 Q2 | 14.85 Billion KRW | -10.18% |
| 2019 Q1 | 18.46 Billion KRW | -7.23% |
| 2019 Q4 | 18.41 Billion KRW | 17.82% |
| 2019 FY | 18.41 Billion KRW | -7.48% |
| 2019 Q3 | 15.63 Billion KRW | -8.62% |
| 2019 Q2 | 17.1 Billion KRW | -7.36% |
| 2018 FY | 19.9 Billion KRW | -21.94% |
| 2018 Q4 | 19.9 Billion KRW | -7.14% |
| 2018 Q3 | 21.43 Billion KRW | -12.5% |
| 2018 Q2 | 24.5 Billion KRW | -2.0% |
| 2018 Q1 | 25 Billion KRW | -1.96% |
| 2017 Q3 | 26 Billion KRW | -1.89% |
| 2017 Q4 | 25.5 Billion KRW | -1.92% |
| 2017 FY | 25.5 Billion KRW | -7.27% |
| 2017 Q2 | 26.5 Billion KRW | 0.0% |
| 2016 FY | 27.5 Billion KRW | 450.0% |
| 2015 FY | 5 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 67.361% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 97.797% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 85.099% |
| HANDOK Inc. | 123.78 Billion KRW | 96.403% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -835.801% |
| Yuhan Corporation | 60.23 Billion KRW | 92.609% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 97.252% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -4272.521% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 94.573% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -654.182% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 26.413% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 75.964% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 64.622% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -178.451% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 67.361% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -3619.973% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 96.321% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 86.087% |
| JW Holdings Corporation | 20.65 Billion KRW | 78.448% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 69.97% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 85.16% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 85.16% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -1933.241% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -666.733% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 91.018% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 67.361% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 76.602% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 95.234% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 85.16% |
| Yuhan Corporation | 60.23 Billion KRW | 92.609% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 57.6% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 88.974% |
| Suheung Co., Ltd. | 74 Billion KRW | 93.984% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 85.16% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -6.849% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 59.389% |
| CKD Bio Corp. | 69.43 Billion KRW | 93.588% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 87.124% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 72.395% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -1349.899% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -1933.241% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 93.826% |
| Boryung Corporation | 151.7 Billion KRW | 97.065% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 94.33% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 26.413% |
| JW Lifescience Corporation | 168 Million KRW | -2550.003% |